Obesity-PSA relationship: a new formula.

Area of Science:

• Urology
• Oncology
• Biostatistics

Background:

• Obesity is associated with lower Prostate-Specific Antigen (PSA) levels, potentially masking prostate cancer.
• Existing PSA screening methods lack accuracy in obese individuals, leading to missed diagnoses.
• A need exists for a formula to correct PSA values based on Body Mass Index (BMI).

Purpose of the Study:

• To introduce and validate a novel BMI-PSA adjusted formula (Hekal's equation) for enhanced PSA sensitivity in obese patients.
• To assess the impact of the adjusted PSA formula on prostate cancer detection rates, particularly in the fifth and sixth decades of life.

Main Methods:

• A new formula, Hekal's equation, was developed: (measured total PSA × age) / BMI.
• The formula was applied to 1000 patient cases with varying PSA, BMI, and age.
• Results were correlated with trans-rectal ultrasound biopsy findings and age-specific PSA values.

Main Results:

• Obesity (BMI > 30 kg/m²) was prevalent in 31.7% of the study population.
• Low measured PSA values in obese men (fifth/sixth decades) led to a potential 53.3% miss rate for malignancy.
• Hekal's equation corrected PSA values, increasing them from 2.1 to 4 ng/mL and 3.8 to 9.3 ng/mL in specific obese groups, thereby aiding biopsy decisions.
• Adjusted PSA showed 41.7% specificity and 70% sensitivity at a 4 ng/mL cutoff.

Conclusions:

• Hekal's equation is a reproducible and easily applicable formula to enhance PSA test sensitivity in obese patients.
• The adjusted PSA values improve the detection of prostate cancer in obese individuals, particularly in middle-aged men.
• This formula corrects misleadingly low PSA readings in obese patients, reducing the risk of missed prostate cancer diagnoses.